Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nippon Kayaku Wins Reversal in Elplat Patent Suit
Nippon Kayaku said on December 8 that it has won a patent infringement suit filed by Swiss-based Debiopharm International SA over the anticancer agent Elplat (oxaliplatin) as the Intellectual Property High Court reversed a lower court ruling. Debiopharm filed the…
To read the full story
Related Article
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Nippon Kayaku Clinches Supreme Court Victory in Elplat Patent Suit
October 6, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- Sawai Prevails in Patent Suit over Elplat
December 26, 2016
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…